Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

134.86 -0.42 (-0.31%)
Streaming Delayed Price Updated: 9:53 AM EDT, Jun 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 729,168
Open 133.85
Bid (Size) 134.83 (4)
Ask (Size) 134.87 (8)
Prev. Close 135.28
Today's Range 133.68 - 135.07
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.31%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Week Ahead: What's Next
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
These two drugmakers have a lot more in common than their market-beating potential. 
Via The Motley Fool

Performance

YTD
+32.07%
+32.07%
1 Month
+6.90%
+6.90%
3 Month
+9.24%
+9.24%
6 Month
+27.89%
+27.89%
1 Year
+66.04%
+66.04%

More News

Read More
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
Via The Motley Fool
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
Via The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Where Will Novo Nordisk Be in 10 Years?
Via The Motley Fool
Novo Nordisk Is At The Vanguard Of The Weight Drug Revolution
Via Talk Markets
Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
Via InvestorPlace
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
Via Benzinga
Topics ETFs
Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs
Via Benzinga
Jim Cramer Recommends Buying Apple, Finds This Tech Stock 'Very Interesting'
Via Benzinga
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
Via Benzinga
A New Name in Weight Loss Drugs
Via The Motley Fool
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
Via Benzinga
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
Via InvestorPlace
Topics ETFs
Ozempic Maker Novo Nordisk's Increasing Influence On Denmark's Employment Raises Economic Concerns
Via Benzinga
Topics Economy
Exposures Economy
LifeMD Can Surge on Its GLP-1 Offerings
Via MarketBeat
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
Via The Motley Fool
The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop
Via InvestorPlace
European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday?
Via Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
Via InvestorPlace
Chinese Scientists Achieve World's First Diabetes Cure Using Cell Therapy: Report
Via Benzinga
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.